• +1-646-491-9876
    • +91-20-67278686

    Search

    Synovial Sarcoma - Pipeline Review, H1 2017

    Synovial Sarcoma - Pipeline Review, H1 2017

    • Report Code ID: RW0001709446
    • Category Pharmaceuticals
    • No. of Pages 153
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Synovial Sarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H1 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

    Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 4 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

    Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Synovial Sarcoma - Overview
    Synovial Sarcoma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Synovial Sarcoma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Synovial Sarcoma - Companies Involved in Therapeutics Development
    Adaptimmune Therapeutics Plc
    Advenchen Laboratories LLC
    EpiZyme Inc
    Immune Design Corp
    Immunocore Ltd
    Johnson & Johnson
    Karyopharm Therapeutics Inc
    Merck & Co Inc
    Novartis AG
    OncoTherapy Science Inc
    Pfizer Inc
    Takara Bio Inc
    Synovial Sarcoma - Drug Profiles
    ACXT-3102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AL-3818 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    axitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CMB-305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CUE-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    everolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-3377794 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OTSA-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pembrolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    quisinostat hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    selinexor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SSTC-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tazemetostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TBI-1301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synovial Sarcoma - Dormant Projects
    Synovial Sarcoma - Discontinued Products
    Synovial Sarcoma - Product Development Milestones
    Featured News & Press Releases
    Feb 22, 2016: The completion of phase I clinical study of the anti-cancer therapeutic antibody 'OTSA101' against synovial sarcoma
    Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US
    Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Synovial Sarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
    Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2017
    Synovial Sarcoma - Pipeline by EpiZyme Inc, H1 2017
    Synovial Sarcoma - Pipeline by Immune Design Corp, H1 2017
    Synovial Sarcoma - Pipeline by Immunocore Ltd, H1 2017
    Synovial Sarcoma - Pipeline by Johnson & Johnson, H1 2017
    Synovial Sarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Synovial Sarcoma - Pipeline by Merck & Co Inc, H1 2017
    Synovial Sarcoma - Pipeline by Novartis AG, H1 2017
    Synovial Sarcoma - Pipeline by OncoTherapy Science Inc, H1 2017
    Synovial Sarcoma - Pipeline by Pfizer Inc, H1 2017
    Synovial Sarcoma - Pipeline by Takara Bio Inc, H1 2017
    Synovial Sarcoma - Dormant Projects, H1 2017
    Synovial Sarcoma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Synovial Sarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Adaptimmune Therapeutics Plc
    Advenchen Laboratories LLC
    EpiZyme Inc
    Immune Design Corp
    Immunocore Ltd
    Johnson & Johnson
    Karyopharm Therapeutics Inc
    Merck & Co Inc
    Novartis AG
    OncoTherapy Science Inc
    Pfizer Inc
    Takara Bio Inc

    Request for Sample

    Report Url http://www.reportsweb.com//synovial-sarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//synovial-sarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//synovial-sarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments